

Jesus Blazquez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7417856/publications.pdf>

Version: 2024-02-01

128
papers

8,555
citations

46918

47
h-index

49773

87
g-index

131
all docs

131
docs citations

131
times ranked

7832
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2022, 77, 641-645.	1.3	5
2	Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2021, 76, 338-344.	1.3	7
3	Interplay among Different Fosfomycin Resistance Mechanisms in <i>Klebsiella pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	7
4	Synergistic Quinolone Sensitization by Targeting the <i>recA</i> SOS Response Gene and Oxidative Stress. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	8
5	Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant <i>Escherichia coli</i> Strains in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
6	Control of Genome Stability by EndoMS/NucS-Mediated Non-Canonical Mismatch Repair. Cells, 2021, 10, 1314.	1.8	6
7	Detection of Low-Level Fosfomycin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomycin Susceptibility Determination. Antibiotics, 2020, 9, 802.	1.5	7
8	Contribution of hypermutation to fosfomycin heteroresistance in <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2020, 75, 2066-2075.	1.3	6
9	Specificity and mutagenesis bias of the mycobacterial alternative mismatch repair analyzed by mutation accumulation studies. Science Advances, 2020, 6, eaay4453.	4.7	30
10	4-Amino-1,2,4-triazole-3-thione as a Promising Scaffold for the Inhibition of Serine and Metallo- β -Lactamases. Pharmaceuticals, 2020, 13, 52.	1.7	13
11	Effect of subinhibitory concentrations of ampicillin on <i>Listeria monocytogenes</i> . Enfermedades Infecciosas Y Microbiología Clínica, 2020, 38, 72-75.	0.3	1
12	Suppression of the SOS response modifies spatiotemporal evolution, post-antibiotic effect, bacterial fitness and biofilm formation in quinolone-resistant <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2019, 74, 66-73.	1.3	17
13	Seawater salt-trapped <i>Pseudomonas aeruginosa</i> survives for years and gets primed for salinity tolerance. BMC Microbiology, 2019, 19, 142.	1.3	11
14	Phenylboronic Acids Probing Molecular Recognition against Class A and Class C β -lactamases. Antibiotics, 2019, 8, 171.	1.5	9
15	N-acetylcysteine blocks SOS induction and mutagenesis produced by fluoroquinolones in <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2019, 74, 2188-2196.	1.3	33
16	Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPC β : A Step against Bacterial Resistance. ChemMedChem, 2018, 13, 713-724.	1.6	24
17	Urinary Tract Conditions Affect Fosfomycin Activity against <i>Escherichia coli</i> Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	22
18	Nanostructured hybrid device mimicking bone extracellular matrix as local and sustained antibiotic delivery system. Microporous and Mesoporous Materials, 2018, 256, 165-176.	2.2	14

#	ARTICLE	IF	CITATIONS
19	In silico identification and experimental validation of hits active against KPC-2 β -lactamase. PLoS ONE, 2018, 13, e0203241.	1.1	9
20	Antibiotic-Induced Genetic Variation: How It Arises and How It Can Be Prevented. Annual Review of Microbiology, 2018, 72, 209-230.	2.9	81
21	Clay-induced DNA breaks as a path for genetic diversity, antibiotic resistance, and asbestos carcinogenesis. Scientific Reports, 2018, 8, 8504.	1.6	8
22	Susceptibility to R-pyocins of <i>Pseudomonas aeruginosa</i> clinical isolates from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2018, 73, 2770-2776.	1.3	19
23	Parallel Evolution of High-Level Aminoglycoside Resistance in <i>Escherichia coli</i> Under Low and High Mutation Supply Rates. Frontiers in Microbiology, 2018, 9, 427.	1.5	28
24	Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in <i>Acinetobacter baumannii</i> . Journal of Antimicrobial Chemotherapy, 2018, 73, 2960-2968.	1.3	28
25	Molecular insights into fosfomycin resistance in <i>Escherichia coli</i> . Journal of Antimicrobial Chemotherapy, 2017, 72, dkw573.	1.3	29
26	Plasmidic <i>qnr</i> Genes Confer Clinical Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	8
27	Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. Clinical Microbiology and Infection, 2017, 23, 325-331.	2.8	38
28	A non-canonical mismatch repair pathway in prokaryotes. Nature Communications, 2017, 8, 14246.	5.8	100
29	Design, synthesis and biological evaluation of non-covalent AmpC β -lactamases inhibitors. Medicinal Chemistry Research, 2017, 26, 975-986.	1.1	11
30	Ciprofloxacin-Mediated Mutagenesis Is Suppressed by Subinhibitory Concentrations of Amikacin in <i>Pseudomonas aeruginosa</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	16
31	Synergistic activity of fosfomycin, β -lactams and peptidoglycan recycling inhibition against <i>Pseudomonas aeruginosa</i> . Journal of Antimicrobial Chemotherapy, 2017, 72, 448-454.	1.3	25
32	Quinolone Resistance Reversion by Targeting the SOS Response. MBio, 2017, 8, .	1.8	54
33	Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo- β -lactamases. Scientific Reports, 2017, 7, 17716.	1.6	35
34	Cellular Response to Ciprofloxacin in Low-Level Quinolone-Resistant <i>Escherichia coli</i> . Frontiers in Microbiology, 2017, 8, 1370.	1.5	21
35	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm <i>Pseudomonas aeruginosa</i> against the innate immune system. PLoS ONE, 2017, 12, e0181932.	1.1	32
36	Intrapopulation variability in mutator prevalence among urinary tract infection isolates of <i>Escherichia coli</i> . Clinical Microbiology and Infection, 2016, 22, 566.e1-566.e7.	2.8	20

#	ARTICLE	IF	CITATIONS
37	Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4252-4258.	1.4	20
38	Determinants of Genetic Diversity of Spontaneous Drug Resistance in Bacteria. <i>Genetics</i> , 2016, 203, 1369-1380.	1.2	7
39	Evolution of <i>Pseudomonas aeruginosa</i> Antimicrobial Resistance and Fitness under Low and High Mutation Rates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1767-1778.	1.4	170
40	Can Clays in Livestock Feed Promote Antibiotic Resistance and Virulence in Pathogenic Bacteria?. <i>Antibiotics</i> , 2015, 4, 299-308.	1.5	9
41	Bypass of genetic constraints during mutator evolution to antibiotic resistance. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2015, 282, 20142698.	1.2	45
42	High Recombinant Frequency in Extraintestinal Pathogenic <i>Escherichia coli</i> Strains. <i>Molecular Biology and Evolution</i> , 2015, 32, 1708-1716.	3.5	21
43	<i>N</i> -Acetylcysteine Selectively Antagonizes the Activity of Imipenem in <i>Pseudomonas aeruginosa</i> by an OprD-Mediated Mechanism. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3246-3251.	1.4	16
44	The <i>Pseudomonas aeruginosa</i> CreBC Two-Component System Plays a Major Role in the Response to β -Lactams, Fitness, Biofilm Growth, and Global Regulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5084-5095.	1.4	56
45	Antibiotics and antibiotic resistance: A bitter fight against evolution. <i>International Journal of Medical Microbiology</i> , 2013, 303, 293-297.	1.5	171
46	β -lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelity. <i>Nature Communications</i> , 2013, 4, 1610.	5.8	320
47	Lysine Trimethylation of EF-Tu Mimics Platelet-Activating Factor To Initiate <i>Pseudomonas aeruginosa</i> Pneumonia. <i>MBio</i> , 2013, 4, e00207-13.	1.8	42
48	Mutational Spectrum Drives the Rise of Mutator Bacteria. <i>PLoS Genetics</i> , 2013, 9, e1003167.	1.5	46
49	The Animal Food Supplement Sepiolite Promotes a Direct Horizontal Transfer of Antibiotic Resistance Plasmids between Bacterial Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2651-2653.	1.4	34
50	Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. <i>Antibiotics</i> , 2013, 2, 217-236.	1.5	151
51	Genomewide Overexpression Screen for Fosfomycin Resistance in <i>Escherichia coli</i> : MurA Confers Clinical Resistance at Low Fitness Cost. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2767-2769.	1.4	48
52	Intrinsic and Environmental Mutagenesis Drive Diversification and Persistence of <i>Pseudomonas aeruginosa</i> in Chronic Lung Infections. <i>Journal of Infectious Diseases</i> , 2012, 205, 121-127.	1.9	61
53	Exposure to diverse antimicrobials induces the expression of <i>qnrB1</i> , <i>qnrD</i> and <i>smaqnr</i> genes by SOS-dependent regulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2854-2859.	1.3	32
54	Simple DNA transformation in <i>Pseudomonas</i> based on the Yoshida effect. <i>Journal of Microbiological Methods</i> , 2012, 89, 95-98.	0.7	13

#	ARTICLE	IF	CITATIONS
55	Antimicrobials as promoters of genetic variation. <i>Current Opinion in Microbiology</i> , 2012, 15, 561-569.	2.3	161
56	The <i>Escherichia coli</i> SOS Gene <i>dinF</i> Protects against Oxidative Stress and Bile Salts. <i>PLoS ONE</i> , 2012, 7, e34791.	1.1	36
57	Effect of <i>recA</i> inactivation on mutagenesis of <i>Escherichia coli</i> exposed to sublethal concentrations of antimicrobials. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 531-538.	1.3	139
58	Estimating mutation rates in low-replication experiments. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 714, 26-32.	0.4	15
59	The K ⁺ uptake regulator <i>TrkA</i> controls membrane potential, pH homeostasis and multidrug susceptibility in <i>Mycobacterium smegmatis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1489-1498.	1.3	34
60	Antagonistic Interactions of <i>Pseudomonas aeruginosa</i> Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4560-4568.	1.4	58
61	Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for <i>P. aeruginosa</i> Infections. <i>PLoS ONE</i> , 2010, 5, e10193.	1.1	37
62	Frequency of Spontaneous Resistance to Fosfomycin Combined with Different Antibiotics in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4948-4949.	1.4	24
63	A MATE-Family Efflux Pump Rescues the <i>Escherichia coli</i> 8-Oxoguanine-Repair-Deficient Mutator Phenotype and Protects Against H ₂ O ₂ Killing. <i>PLoS Genetics</i> , 2010, 6, e1000931.	1.5	33
64	The <i>Pseudomonas aeruginosa</i> <i>pfpl</i> Gene Plays an Antimutator Role and Provides General Stress Protection. <i>Journal of Bacteriology</i> , 2009, 191, 844-850.	1.0	48
65	The Glycerol-3-Phosphate Permease <i>GlpT</i> Is the Only Fosfomycin Transporter in <i>Pseudomonas aeruginosa</i> . <i>Journal of Bacteriology</i> , 2009, 191, 6968-6974.	1.0	102
66	Î²-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein. <i>PLoS Pathogens</i> , 2009, 5, e1000353.	2.1	258
67	Inactivation of the <i>hmgA</i> gene of <i>Pseudomonas aeruginosa</i> leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. <i>Microbiology (United Kingdom)</i> , 2009, 155, 1050-1057.	0.7	124
68	Side effects of antibiotics on genetic variability. <i>FEMS Microbiology Reviews</i> , 2009, 33, 531-538.	3.9	89
69	Effect of Subinhibitory Concentrations of Antibiotics on Intrachromosomal Homologous Recombination in <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3411-3415.	1.4	74
70	The evolution of contact-dependent inhibition in non-growing populations of <i>Escherichia coli</i> . <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2008, 275, 3-10.	1.2	33
71	A novel role for <i>RecA</i> under non-stress: promotion of swarming motility in <i>Escherichia coli</i> K-12. <i>BMC Biology</i> , 2007, 5, 14.	1.7	69
72	Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in <i>Escherichia coli</i> . <i>Molecular Microbiology</i> , 2007, 64, 83-93.	1.2	115

#	ARTICLE	IF	CITATIONS
73	Multidrug-resistant <i>Mycobacterium tuberculosis</i> , Bangui, Central African Republic. <i>Emerging Infectious Diseases</i> , 2006, 12, 1454-1456.	2.0	16
74	Determination of the structure of a hybrid between 2-(1,4-benzoquinone)acetic acid and a linear peptide by electrospray ionization mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 512-516.	0.7	3
75	In vitro plasmid-encoded resistance to quinolones. <i>FEMS Microbiology Letters</i> , 2006, 154, 271-276.	0.7	10
76	PBP3 inhibition elicits adaptive responses in <i>Pseudomonas aeruginosa</i> . <i>Molecular Microbiology</i> , 2006, 62, 84-99.	1.2	97
77	Identification of Nudix Hydrolase Family Members with an Antimutator Role in <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium smegmatis</i> . <i>Journal of Bacteriology</i> , 2006, 188, 3159-3161.	1.0	38
78	Autogenous and nonautogenous control of response in a genetic network. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12718-12723.	3.3	57
79	SOS-Independent Induction of <i>dinB</i> Transcription by β -Lactam-Mediated Inhibition of Cell Wall Synthesis in <i>Escherichia coli</i> . <i>Journal of Bacteriology</i> , 2005, 187, 1515-1518.	1.0	105
80	Hypermutation and the Preexistence of Antibiotic-Resistant <i>Pseudomonas aeruginosa</i> Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4226-4233.	1.4	138
81	Aza-boronic acids as non- β -lactam inhibitors of AmpC- β -lactamase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3979-3983.	1.0	14
82	Recognition and Resistance in TEM β -Lactamase. <i>Biochemistry</i> , 2003, 42, 8434-8444.	1.2	47
83	Nanomolar Inhibitors of AmpC β -Lactamase. <i>Journal of the American Chemical Society</i> , 2003, 125, 685-695.	6.6	123
84	Hypermutation as a Factor Contributing to the Acquisition of Antimicrobial Resistance. <i>Clinical Infectious Diseases</i> , 2003, 37, 1201-1209.	2.9	181
85	Mutations in Putative Mutator Genes of <i>Mycobacterium tuberculosis</i> Strains of the W-Beijing Family. <i>Emerging Infectious Diseases</i> , 2003, 9, 838-845.	2.0	240
86	Very Low Cefotaxime Concentrations Select for Hypermutable <i>Streptococcus pneumoniae</i> Populations. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 528-530.	1.4	41
87	Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?. <i>Current Drug Targets</i> , 2002, 3, 345-349.	1.0	57
88	The mismatch repair system (<i>mutS</i> , <i>mutL</i> and <i>uvrD</i> genes) in <i>Pseudomonas aeruginosa</i> : molecular characterization of naturally occurring mutants. <i>Molecular Microbiology</i> , 2002, 43, 1641-1650.	1.2	243
89	Characterization of the GO system of <i>Pseudomonas aeruginosa</i> . <i>FEMS Microbiology Letters</i> , 2002, 217, 31-35.	0.7	47
90	Structure-based design and in-parallel synthesis of inhibitors of AmpC β -lactamase. <i>Chemistry and Biology</i> , 2001, 8, 593-610.	6.2	45

#	ARTICLE	IF	CITATIONS
91	Antibiotic resistance in hospital infections: the role of newer cephalosporins. <i>Clinical Microbiology and Infection</i> , 2000, 6, 95-97.	2.8	1
92	Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. <i>Aids</i> , 2000, 14, F1-F7.	1.0	80
93	Concentration-Dependent Selection of Small Phenotypic Differences in TEM β -Lactamase-Mediated Antibiotic Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2485-2491.	1.4	114
94	Selection of Naturally Occurring Extended-Spectrum TEM β -Lactamase Variants by Fluctuating β -Lactam Pressure. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2182-2184.	1.4	57
95	ACI-1 from <i>Acidaminococcus fermentans</i> : Characterization of the First β -Lactamase in Anaerobic Cocci. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3144-3149.	1.4	24
96	Biological Cost of AmpC Production for <i>Salmonella enterica</i> Serotype Typhimurium. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3137-3143.	1.4	90
97	High Frequency of Hypermutable <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Lung Infection. <i>Science</i> , 2000, 288, 1251-1253.	6.0	1,322
98	Molecular Markers Demonstrate that the First Described Multidrug-Resistant <i>Mycobacterium bovis</i> Outbreak Was Due to <i>Mycobacterium tuberculosis</i> . <i>Journal of Clinical Microbiology</i> , 1999, 37, 971-975.	1.8	30
99	<i>Mycobacterium tuberculosis</i> subsp. <i>caprae</i> subsp. nov.: A taxonomic study of a new member of the <i>Mycobacterium tuberculosis</i> complex isolated from goats in Spain. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 1999, 49, 1263-1273.	0.8	152
100	The complexed structure and antimicrobial activity of a non- β -lactam inhibitor of AmpC β -lactamase. <i>Protein Science</i> , 1999, 8, 2330-2337.	3.1	66
101	An extended-spectrum AmpC-type β -lactamase obtained by in vitro antibiotic selection. <i>FEMS Microbiology Letters</i> , 1998, 165, 85-90.	0.7	33
102	Identification as <i>Mycobacterium tuberculosis</i> of previously described <i>M bovis</i> multidrug-resistant strains. <i>Lancet, The</i> , 1998, 351, 758.	6.3	6
103	Structure-Based Enhancement of Boronic Acid-Based Inhibitors of AmpC β -Lactamase. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4577-4586.	2.9	139
104	Antibiotic-Selective Environments. <i>Clinical Infectious Diseases</i> , 1998, 27, S5-S11.	2.9	197
105	Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. <i>Aids</i> , 1998, 12, F131-F135.	1.0	117
106	A237T as a Modulating Mutation in Naturally Occurring Extended-Spectrum TEM-Type β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 1042-1044.	1.4	33
107	Allele-Specific PCR Method Based on <i>pncA</i> and <i>oxyR</i> Sequences for Distinguishing <i>Mycobacterium bovis</i> from <i>Mycobacterium tuberculosis</i> : Intraspecific <i>M. bovis pncA</i> Sequence Polymorphism. <i>Journal of Clinical Microbiology</i> , 1998, 36, 239-242.	1.8	71
108	Selection of very small differences in bacterial evolution. <i>International Microbiology</i> , 1998, 1, 295-300.	1.1	16

#	ARTICLE	IF	CITATIONS
109	Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by <i>Mycobacterium bovis</i> . <i>Aids</i> , 1997, 11, 1237-1242.	1.0	76
110	Evolution of antibiotic resistance. <i>Trends in Ecology and Evolution</i> , 1997, 12, 482-487.	4.2	126
111	Nosocomial transmission of <i>Mycobacterium bovis</i> resistant to 11 drugs in people with advanced HIV-1 infection. <i>Lancet</i> , 1997, 350, 1738-1742.	6.3	108
112	H-NS and RpoS regulate emergence of Lac Ara+ mutants of <i>Escherichia coli</i> MCS2. <i>Journal of Bacteriology</i> , 1997, 179, 4620-4622.	1.0	44
113	The Antibiotic Selective Process: Concentration-Specific Amplification of Low-Level Resistant Populations. <i>Novartis Foundation Symposium</i> , 1997, 207, 93-111.	1.2	27
114	Genetic characterization of multidrug-resistant <i>Mycobacterium bovis</i> strains from a hospital outbreak involving human immunodeficiency virus-positive patients. <i>Journal of Clinical Microbiology</i> , 1997, 35, 1390-1393.	1.8	85
115	Cyclic AMP receptor protein positively controls <i>gyrA</i> transcription and alters DNA topology after nutritional upshift in <i>Escherichia coli</i> . <i>Journal of Bacteriology</i> , 1996, 178, 3331-3334.	1.0	47
116	Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) beta-lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 2434-2436.	1.4	53
117	<i>hns</i> mutant unveils the presence of a latent haemolytic activity in <i>Escherichia coli</i> K-12. <i>Molecular Microbiology</i> , 1996, 19, 909-910.	1.2	18
118	Characterization of a Nosocomial Outbreak Involving an Epidemic Plasmid Encoding for TEM-27 in <i>Salmonella enterica</i> Subspecies <i>enterica</i> Serotype Othmarschen. <i>Journal of Infectious Diseases</i> , 1996, 174, 1015-1020.	1.9	52
119	New extended-spectrum TEM-type beta-lactamase from <i>Salmonella enterica</i> subsp. <i>enterica</i> isolated in a nosocomial outbreak. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 458-461.	1.4	72
120	Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM beta-lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 145-149.	1.4	63
121	In-vitro synergy between aminoglycosides deployed against <i>Staphylococcus</i> spp. harbouring a 6-aminoglycoside acetyltransferase, 2-aminoglycoside phosphotransferase enzyme. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 747-755.	1.3	3
122	Non-canonical mechanisms of antibiotic resistance. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1994, 13, 1015-1022.	1.3	17
123	Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 2059-2063.	1.4	168
124	Bleomycin increases amikacin and streptomycin resistance in <i>Escherichia coli</i> harboring transposon Tn5. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 1982-1985.	1.4	7
125	PCR and hemodialysis patients. <i>Clinical Nephrology</i> , 1993, 40, 121-2.	0.4	1
126	Mutations in the <i>aphA-2</i> gene of transposon Tn5 mapping within the regions highly conserved in aminoglycoside-phosphotransferases strongly reduce aminoglycoside resistance. <i>Molecular Microbiology</i> , 1991, 5, 1511-1518.	1.2	26

#	ARTICLE	IF	CITATIONS
127	Bleomycin-kanamycin resistance as a marker of the presence of transposon Tn5 in clinical strains of Escherichia coli. European Journal of Clinical Microbiology and Infectious Diseases, 1989, 8, 995-998.	1.3	6
128	A clinical isolate of transposon Tn5 expressing streptomycin resistance in Escherichia coli. Journal of Bacteriology, 1988, 170, 1275-1278.	1.0	10